Senzime AB (publ) (SNZZF) Q3 2025 Earnings Call Prepared Remarks Transcript

Philip Siberg
Chief Executive Officer

Okay. Good morning, good afternoon, depending on where you are. Welcome to this summary presentation of our first 9 months of 2025 and a little bit deep dive into our third quarter of ’25. So let’s start with a little bit of a high-level summary of what we’ve achieved this year so far.

We’ve had exceptional growth, 80% in constant currencies. Sensor deliveries continue to perform very well with unit growth of 78%. Our underlying gross margin keeps on improving, thanks to decreased production costs.

Our operating expenses are in line with plan, remaining fairly constant, and our EBITDA improved by 20% over the first 9 months. So really, what’s happening here is twofold. We are growing our installed base of TetraGraph systems.

We shipped 553 monitors during the second — during the third quarter, sorry. So that makes our year-to-date shipments 1,723 monitors compared to 776 of last year. So we keep on growing our installed base and delivered units very fast.

Equally, the amount of sensors, which are used on every single patient that the TetraGraph is used for keeps on growing as well. We shipped over 300,000 sensors the last 9 months, and this continues to grow in a very nice exponential growth rate.

If we continue to look at what we’ve done over the last couple of quarters, I mean, we continue to be one of the fastest-growing medical device companies on the NASDAQ main market.

We’ve had a hockey stick type of business since our products came out, since we rolled out a fantastic commercial organization, strong focus on the U.S. market and also have had strong help from clinical